laboratory animal monitoring system. Brain-gut responses were analyzed physiologically. Results VBLOC reduced body weight and food intake, which was associated with increased satiety but not with decreased hunger. Brain activities in response to VBLOC included increased gene expression of leptin and CCKb receptors, interleukin-1β, tumor necrosis factor, and transforming growth factor β1 in the brainstem; increased CCK, somatostatin, and tyrosine hydroxylase in the hippocampus; increased NPY, AgRP, and Foxa2 in the hypothalamus; and reduced CCKb receptor, melanocortin 4 receptor, and insulin receptor in the hypothalamus. Plasma concentrations of CCK, gastrin, glucagon, GLP-1, and PYY and gastric acid secretion were unchanged in response to VBLOC. Conclusions Based on the present study, we may suggest that VBLOC induces satiety through vagal signaling, leading to reduced food intake and loss of body weight.
Introduction
The number of obese individuals is increasing rapidly, leading to a global obesity epidemic. So far, only bariatric surgery has demonstrated long-term therapeutic effects, and therefore, the use of surgery to treat obesity is increasing [1, 2] . Considering the large number of obese patients, the risk of surgical complications and high surgery-related cost, the development of minimal invasive procedures to treat obesity is urgently needed [3] .
The gut-brain axis is known to play an important role in the pathogenesis of obesity. Nutritional and metabolically relevant information is conveyed to the brain by gut-produced hormones and the vagus nerve [4] . The vagus nerve responds to mechanical and chemical stimuli from the gastrointestinal Electronic supplementary material The online version of this article (doi:10.1007/s11695-016-2278-x) contains supplementary material, which is available to authorized users.
Abstract
Background Recently, the US FDA has approved "vagal blocking therapy or vBLoc therapy" as a new treatment for obesity. The aim of the present study was to study the mechanism-of-action of "VBLOC" in rat models. Methods Rats were implanted with VBLOC, an intraabdominal electrical device with leads placed around gastric vagal trunks through an abdominal incision and controlled by wireless device. Body weight, food intake, hunger/satiety, and metabolic parameters were monitored by a comprehensive ® tract and transmits satiety signals to sites in the central nervous system that regulate eating behavior [5] [6] [7] . Through the nucleus of the tractus solitarius (NTS) in the brainstem, afferent vagal signals may be relayed to reach several parts of the brain including the parabrachial nucleus, reticular formation, hippocampus, amygdala, and hypothalamus [8] . The hypothalamus is regarded as a key regulatory component of a central network for food intake where orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons and anorexigenic pro-opiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART) neurons are thought to play a central role [5] . However, the brainstem also contributes in food intake and body weight regulation [9] . In addition to the regulation of food intake, the vagus nerve also regulates gastric acid production and pancreatic secretion [10, 11] . The central role of the vagus in the regulation of food intake and energy expenditure makes it an ideal target for new less or noninvasive procedures to treat obesity.
Recently, the US FDA has approved "vagal blocking therapy or vBLoc® therapy" by which an intra-abdominal electrical device with leads is placed laparoscopically around the vagus nerve as a new treatment for obesity [12, 13] . The term VBLOC has been often used in clinical trials, patent applications, and the US FDA approval documents. VBLOC was initially believed to be of "vagotomy effect" but in fact this is unlikely as pointed out by the FDA approval letter, i.e., "the specific mechanisms for weight loss due to the use of the device are unknown". Hence, the aim of this study was to study the mechanism-ofaction (MOA). To this end, we utilized animal models to examine how VBLOC impacted upon body weight, food intake, hunger/satiety, eating behavior, metabolic parameters, gut hormone concentrations, gastric acid secretion, and the expression profile of candidate energy balance-regulating genes in the hypothalamus, brainstem, and hippocampus.
Materials and Methods

Animals
Rats (adult, male, Sprague-Dawley) were purchased from Taconic (Ejby, Denmark) and Janvier Labs (France). Rats (adult, female, Long Evan) were obtained at NTNU, Trondheim, Norway. They had free access to tap water and standard rat pellet food (RM1 811004, Scanbur BK AS, Sweden). All animals were housed three to four together in individually ventilated cages on wood chip bedding with a 12-h light/dark cycle, room temperature of 22°C, and 40-60 % relative humidity. The standard housing conditions were specific pathogen free and in agreement with Federation of European Laboratory Animal Science Association (FELASA) recommendations. All animals were euthanized between 0800 and 1000 A.M. Thus, the plasma concentrations of gut hormones measured at euthanization could be considered as postprandial levels. Animal experiments were performed according to the guidelines for the design and statistical analysis of experiments using laboratory animals after being approved by the Norwegian National Animal Research Authority (Forsøksdyrutvalget, FDU). All applicable institutional and national guidelines for the care and use of animals were followed.
In all studies regarding eating behavior, the animals were acclimatized to the Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments International, Columbus, OH, USA) for 24 h before data collection. At data collection, the animals were kept in CLAMS for 48 h and data from the last 24 h were used for analysis. Before CLAMS, the rats were habituated to their normal food as powder for 3 days, as the food in CLAMS is in powder form. Body weight development was followed throughout the study period (three times per week).
Experimental Design
Pilot Experiment
The paradigm of VBLOC between 0.5 and 2.0 mA with 30 Hz, 500 μs, 30 s ON, and 5 min OFF was chosen according to the safety, tolerance, and possible efficacy assessments in response to the long-term VBLOC.
Short-Term VBLOC
In the first experiment, rats (Sprague-Dawley) received VBLOC (2 mA, 30 Hz, 500 μs, 30 s ON, and 5 min OFF) while they were subjected to electrophysiological recording in the hippocampus. In the second experiment, rats (Sprague-Dawley) had implanted gastric fistula and they were acclimatized to Bollman cages for 3 h at three separate occasions before and after VBLOC and gastric fistula implantation, and then subjected to gastric acid secretion measurement (baseline and pentagastrin stimulation). After gastric acid output measurement, VBLOC was turned off. Three days after, rats received VBLOC (2 mA, 30 Hz, 500 μs, 30 s ON, and 5 min OFF) for 48 h while eating behavior and metabolic parameters were measured in CLAMS [14, 15] . The VBLOC and control group consisted of six rats per group. The control group had the same implantations without any stimulation. Immediately after 48 h of VBLOC, the rats were euthanized and brain samples were collected for in situ hybridization, and plasma was collected for radioimmunoassay.
Long-Term VBLOC
In the first experiment (Sprague-Dawley rats), VBLOC was started 4 weeks after implantation of device and it was constantly ON while the current (mA) was gradually increased for 6-8 weeks. Each rat was placed in CLAMS at four time points for measurements of eating behavior and metabolic parameters; 3 weeks after VBLOC implantation (before stimulation, baseline), at 0.5mA stimulation, at 1mA stimulation, and at 2mA stimulation. The settings were 30 Hz, pulse width 500 μs, and the ON and OFF time were 30 s and 5 min. VBLOC and control group consisted of nine and four rats per group. The control group had the same implantation with no stimulation. At euthanization, brain samples were taken for Taqman array analysis and RNA sequencing, and plasma was collected for radioimmunoassay. In the second experiment (Long Evan rats), we developed smaller VBLOC devices (μVBLOC) due to devicesize-related irritation. µVBLOC and control group consisted of four rats per group, and µVBLOC was continuously ON at 2 mA, 30 Hz, 500 μs, 30 s ON, and 5 min OFF for 2 weeks. At euthanization, plasma was collected for radioimmunoassay.
Statistical Analysis
The results are expressed as mean ± SEM. Statistical comparisons were performed using independent t test between the surgical groups. ANCOVA with Sidak test was performed for energy expenditure statistics, while ANOVA with Tukey's test was performed to determine eating behavior and metabolic parameters. A p value of <0.05 (two tailed) was considered statistically significant. The data analysis was performed in SPSS version 15.0 and 20.0.
Supplementary Materials and Methods
Information regarding animal surgery, determination of eating behavior and metabolic parameters, gastric acid output measurement, Taqman array, in situ hybridization, RNA sequencing, radioimmunoassay, in vivo electrophysiology, and statistical analysis are provided in the Supplementary Materials and Methods.
Results
Electrophysiology tetrodes recorded VBLOC-induced activity in the brain (Fig. 1a) . In response to the short-term VBLOC (48 h at Fig. 1 The effects of short-term VBLOC. a In vivo electrophysiological recordings of stimulation-induced activity in the brain. The graph depicts the average waveform of measured activity; the insert shows the raw data from which the average waveform was constructed. b Effects of shortterm VBLOC (48 h) on mRNA expression of NPY, AgRP, and POMC in the arcuate nucleus (ARC) and dorsomedial hypothalamic nucleus (DMH). *p < 0.05 between sham-VBLOC (white) and VBLOC (black). c Effect of short-term VBLOC (48 h) on NPY expression in the brainstem. Note: no significant difference between sham-VBLOC (white) and VBLOC (black). d, e Effects of short-term VBLOC (48 h) on plasma concentrations of gut hormones. Note: no significant difference between sham-VBLOC (white) and VBLOC (black). f Effects of VBLOC on baseline and pentagastrin (PG)-stimulated gastric acid secretion. Note: no significant difference between any VBLOC currents with or without PG injection 2-mA current), gene expression of NPYand AgRP in the arcuate nucleus (ARC) of the hypothalamus as well as NPY gene expression in dorsomedial hypothalamic nucleus (DMH) were upregulated, but NPY gene expression in the brainstem, and plasma concentrations of gut hormones were unchanged (Fig. 1b-d) . On the other hand, basal and pentagastrin-stimulated gastric acid secretions were unchanged in response to the short-term VBLOC (Fig. 1e) .
During the short-term VBLOC (48 h at 2mA current), there were no changes in body weight, food intake, eating behavior, and metabolic parameters including energy expenditure ( Table 1 ). The animals showed no signs of discomfort stemming from the VBLOC.
In response to the long-term VBLOC in which the current was gradually increased (from 0.5 to 2 mA), the body weight and food intake (g) were reduced as the current was increased, eventually reaching reductions of 10 % (p > 0.05) and 30 % (p < 0.05), respectively (Fig. 2a-c) . Energy expenditure (kcal/h/body weight) was reduced compared to baseline values (Fig. 2d) . Satiety ratio particularly during nighttime was increased, but number of meals ("hunger index") was unchanged (Fig. 2e, f) . When the current was started at 2 mA, a 10 % body weight reduction was achieved within 1 week (p < 0.05) (Fig. 2a) . Additional parameters of eating behavior and metabolism were unchanged after the long-term VBLOC ( Table 2) . Analysis of the hypothalamus showed a significant increase in gene expression of NPY and forkhead box protein A2 (Foxa2), a decrease for cholecystokinin b (CCKb) receptor, and a tendency for decreased expression of the melanocortin 4 receptor (MC4R) and insulin receptor (Insr) (Fig. 3a) . In the brainstem, the gene expression of leptin and CCKb receptors, and interleukin-1β (IL1b), tumor necrosis factor (Tnf), and transforming growth factor β1 (Tgfb1) was increased (Fig. 3b) . In the hippocampus, VBLOC increased expression of CCK, somatostatin and tyrosine hydroxylase (crucial for the production of dopamine) (Fig. 3c) . The plasma concentrations of CCK, gastrin, glucagon, glucagonlike peptide-1 (GLP-1), and peptide YY (PYY) were unchanged (Fig. 3d) .
Discussion
The brain-gut axis functions in both afferent and efferent directions via the vagus nerve. To examine the effects of VBLOC on either efferent or afferent or both directions, the gut responses (gastric acid secretion and gut hormones) and the brain responses (electrical activity and gene expression) were analyzed. VBLOC Fig. 2 The effects of long-term VBLOC on body weight, eating behavior, and metabolic parameters. a Effects of different currents of VBLOC on body weight. Note: when current was started at 2 mA, a weight reduction was accomplished instantly (p < 0.05) (white). b Effects of long-term VBLOC on food intake (g/24 h). *p < 0.05 between sham-VBLOC (white) and VBLOC (black). c Effects of longterm VBLOC on food intake (g/100 g body weight). *p < 0.05 between values before VBLOC and at 2 mA. Note: white columns represent sham-VBLOC, and black columns represent VBLOC. d Effect of long-term VBLOC on energy expenditure (kcal/h/body weight). **p < 0.01 between values before VBLOC and at 2 mA (ANCOVA with Sidak test). Note: white columns represent sham-VBLOC, and black columns represent VBLOC. e Effects of long-term VBLOC on satiety ratio (min/g) during nighttime. Note: p < 0.05 (one-tailed) between sham-VBLOC (white) and VBLOC (black) at 2 mA. f Effects of long-term VBLOC on number of meals (24 h). Note: no significant difference between sham-VBLOC (white) and VBLOC (black) was originally derived from vagus nerve stimulation. In the neuromodulation spectrum, it has been postulated that lowfrequency electrical impulses increases the neurophysiologic activity and hence resulting in neurostimulation. The converse occurs with higher frequency electrical impulses resulting in neuroblocking. In the present study, the two electrodes of VBLOC were wrapped around both the anterior and posterior nerve branches together with extra tissue from the esophagus. The cathode was placed on the proximal part and anode on the distal part (Fig. 4a) . During VBLOC the cathode induced depolarization, leading to a stimulation of the afferent fibers. The afferent fibers are believed to be involved in the sensory feedback on satiety, satiation and energy metabolism. As shown in the present study, VBLOC induced satiety signaling in the brainstem and satiety ratio (but not hunger) in eating behavior. During VBLOC the distal anode hyperpolarized the membrane and imposed an anodic block on the efferent fibers (Fig. 4b) . The stimulation of vagus nerve is known to induce gastric acid secretion via the efferent fibers on the parietal cells and the gastrinproducing G cells in the stomach [16, 17] . As shown in the present study, VNS was without affecting the acid secretion and gut hormones (particularly gastrin, CCK, GLP-1, and PYY), indicating a functional blockade of vagal efferent fibers, named as VBLOC. The application of VBLOC in the long-term (6-8 weeks) particularly with the application of highest current (2 weeks) resulted in reduced food intake and body weight in the rat model. Previously, several animal studies reported reduced body weight gain and food intake in response to VNS which was applied mostly at the left vagal branch in the neck. However, the results reported were of low quality due to large variations, and no SD or SEM in the figures [18] [19] [20] [21] [22] [23] . In the present study, the short-term (48 h) VBLOC was unable to alter eating behavior. However, the long-term (6-8 weeks) VBLOC, particularly when being started with a high current (2 weeks), reduced food intake, and body weight. This is in line with a report that subdiaphragmatic VNS attenuated weight gain in obese minipigs during 14 weeks [24] .
It should be noticed that in response to VBLOC the gene expression, especially NPY/AgRP, in the hypothalamus was unexpectedly changed with a drive for increased food intake and a reduction in energy expenditure [5, [25] [26] [27] . However, the gene expression in the brainstem and the hippocampus were changed, which was compatible with an anorexigenic drive in response to VBLOC, being consistent with the weight loss. The brainstem is the first target for vagal afferent fibers in the central nervous system. VBLOC-induced afferent signals can be sent from the brainstem to the hippocampus, as also seen in previous studies [28] . In fact, the hippocampus is not only involved in memory but also has a role in incentive motivation (e.g., for food), in the processing of hormonal signals (CCK, ghrelin, and motilin), and in the regulation of food intake [29] [30] [31] [32] [33] .
Gut hormones are thought to be central in appetite regulation in the gut-brain axis, and satiety hormones such as CCK, glucagon, GLP-1, and PYY are known to reduce food intake [4] . However, these gut hormones were unaltered after VBLOC neither in short-term nor in long-term. Thus, we speculate that there are the two pathways, i.e., gut hormone-hypothalamus and vagus nerve-brainstem, within the gut-brain axis and that these are independent each other. Ghrelin levels were not included due to a technical problem. However, it is unlikely that ghrelin plays a role in VBLOC-induced weight loss, as the hunger index was unchanged neither during daytime nor during nighttime.
Taken together, we may suggest the possible mechanismof-action of VBLOC in which it activates the vagal signaling to the brainstem and hippocampus and blocks the vagal signaling to the gut, leading to increased satiety, reduced food intake and eventually loss of body weight. It is our hope that this study will serve as the basis for many more experimental studies to better understand the mechanism-of-action of VBLOC therapy in the future.
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